Tinjauan Pustakaa Peranan ACEIs. ARB dan ARNI pada Penyakit Ginjal Kronik
DOI:
https://doi.org/10.56260/sciena.v5i2.322Keywords:
Penyakit ginjak kronik (PGK), Penyakit kardiovaskular (PKV), Renin Angiotensin Aldosteron System (RAAS)Abstract
Latar Belakang: Penyakit ginjal kronik (PGK) dan penyakit kardiovaskular (PKV) merupakan dua kondisi berkaitan dan sering muncul bersamaan. Penggunaan obat yang bekerja di sistem renin angiotensin aldosteron (RAA) eperti golongan ACEIs, ARB, dan ARNI merupakan pilihan utama pada hipertensi dan bagian pilar utama terapi pada gagal jantung fraksi ejeksi rendah. Efek samping hiperkalemia dan peningkatan kreatinin serum sering menjadi alasan bagi klinisi untuk tidak memberikan ACEIs/ARB pada pasien PGK. Metode: Pendekatan narrative review, sumber literatur dari Pubmed, Google Scholar dan Science Direct dengan kata kunci PGK, PKV, RAAS inhibitor. Kriteria inklusi berupa artikel sesuai tema penelitian, artikel terindeks scopus dan diterbitkan tahun 2016 – 2025. Kriteria eksklusi meliputi artikel yang tidak dapat diakses, tidak menjawab jenis review. Hasil: Penggunaan obat yang bekerja di sistem RAA pada PGK aman dan memberikan outcome yang baik. Penghentian terapi akan meningkatkan risiko progresivitas end stage renal disease (ERSD) 1,29 kali dan insiden PKV 1,38 kali. Kesimpulan: Penggunaan obat yang bekerja di sistem RAA seperti golongan ACEIs, ARB, dan ARNI pada pasien PGK aman, efektif dan memberikan outcome yang lebih baik.
References
. Kidney Disease Improving Global Outcome. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. 2024;105(4).
. PERNEFRI. 11th Report of Indonesian Renal Registry 2018. Diakses dari http://indonesian renalregistry.org.
. Whelton P, Carey R, Aronow WS, Casey D, Collins K, Himmerfarb CD, de Palma SM et al. Clinical practice guideline: 2018 AHA guideline for the prevention, detection, evaluation and management of high blood pressure in adult. 2017;1(4):1 – 103.
. Coyle M, Flaherty G, Jennings C. A Critical review of chronic kidney disease as a risk factor for coronary artery disease. IJC Heart and Vasculature. 2021;35(6):1 – 10.
. Ryan DK, Banerjee D, Jouhra F. Management of heart failure in patients with chronic kidney disease. European Cardiology. 2022;4:1 – 9.
. Naveed H, Tirumandyam G, Mohan GVK, Gul S, Ali S, Siddiqui A, Suarez Z K et al. Effect of discontinuation of renin angiotensin-system inhibitors in patients with advanced chronic kidney disease: A meta analysis. Cureus. 2023;15(4):1 – 8.
. Bhailis AM, Kalra PA. Hypertension and the kidney. BR J Hosp Med. 2022;1:1 – 11.
. Lee JH. Relationship between hypertension and declining renal function in korean adults. Korean J Clin Lab Sci. 2021;53(1):32 – 40.
. Ameer O Z. Hypertension in chronic kidney disease: what lies behind the scene. Front Pharmacol. 2022;10:1 – 28.
. Moisi MI, Rus M, Bungau S, Zaha DC, Uivarosan D, Fratila O et al. Acute coronary syndromes in chronic kidney diseas: clinical and therapeutic characteristics.Medicina. 2020;56(3):1 – 15.
. Wetmore JB, Broce M, Malas A, Almehmi A. Painless myocardial iscmhemia is associated with mortality in patients with chronic kidney disease. Nephron Clinical Practice. 2013;122(4): 9 – 16.
. Dusing P, Zietzer A, Goody P R, Hosen MR, Kurts C et al.Vascular pathologies in chronic kidney disease: pathphysiological mechanism and novel therapeutic approach. J Mol Med. 2021;99: 335 – 48.
. Reddy YS, Kiranmayi VS, Bitla AR, Bitla AR, Khrisna GS, Rao S, Sivakumar V. Nitric oxide status in patients with chronic kidney disease. Indian Journal of Nephrology. 2015;25(9):1 – 5.
. Ryan D K, Banerjee D, Jouhra F. Review CVD in CKD patient: Mangement of heart failure in patients with chronic kidney disease. ECR. 2022;4:1 – 9.
. Kidney Disease Improving Global Outcome.KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. 2021;9(3).
. Segall L, Nistor I, dan Covic A. Heart failure ini patients with chronic kidney disease: a systematic integrative review. Biomed Research International. 2014;5:1 – 21.
. Zhang Y, He D, Zhang W, Xing W, Guo Y, Wang F et al. ACE Inhibitor benefit to kidney and cardiovascular outcomes for patients with non dyalsis chronic kidney disease stages 3-5: A network meta analysis of randomised clinical trials. Drugs. 2020;80:797 – 811.
. Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen K L. Use of anthypertensive agents and association with risk of adverse outcomes in chronic kidney disease: Focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blocker. J. Am. Heart Assoc. 2018;7:1 – 13.
. Yang A, Shi M, Lau ES, Wu H, Zhang X, Fan B et al. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prosepective cohort study. eClinical Medicine. 2023;55:1 – 14.
. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al. Renin-angiotensin system inhibitors kidney and cardiovascular outcumes in patients with CKD : A bayesian network metaanalysis of RCT. AJKD. 2015;11.
. Bhandari S, Mehta S, Khawaja A, Cleland J G, Ives N, Cockwell P. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. J Kint. 2024;1.
. Feng Y, Yin Y, Deng R, Li H. Review article: Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2020;45 Hlm.1235-44.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Adefri Wahyudi , Wahyudi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
